Severe Aplastic Anemia
Conditions
Keywords
Avatrombopag, Aplastic Anemia, elderly, sever
Brief summary
This is a multicenter, single-arm clinical study. The objective was to evaluate the efficacy and safety of CSA in combination with Avatrombopag in elderly patients with very/sever aplastic anemia treated for the first time. The design was: cyclosporine 3 mg/kg orally in two divided doses, with cyclosporine trough concentrations maintained at 200-250 ng/ml for 3 months to achieve maximum efficacy, and Avatrombopag, which was administered in two dose groups, 40 mg orally once daily and 60 mg orally once daily, for a total of 24 weeks. Forty patients are expected to be enrolled in each dose group, and a total of 80 patients are expected to be enrolled if both dose groups are conducted. Evaluation endpoint: OR rate at 24 weeks of treatment.
Detailed description
This is a multicenter, single-arm clinical study to evaluate the efficacy and safety of CSA combined with Avatrombopag. The patients are older than 60 years with diagnosis of very sever/sever aplastic anemia(V/SAA) without treatment before. CSA is started at 3 mg/kg orally in two doses. Concentrations maintained at 200-250 ng/ml to achieve maximum efficacy and then tapered by 25 mg every 3 months; Avatrombopag: two dosing groups, 40 mg orally once daily and 60 mg orally once daily, for a total of 24 weeks；Each dose group is expected to include 40 patients each. If the 40 mg dose group trial meets the desired trial objectives, the 60 mg dose group trial will not be conducted, and if the 40 mg dose group does not meet the desired trial objectives, the 60 mg dose group trial will be continued. A total of 80 patients were expected to be included if both dose groups were conducted.Overall response rate at 24 weeks of treatment and adverse events are the evaluation endpoint.Secondary study endpoints were: CRR and ORR at 12 and 52 weeks of treatment, CRR at 24 weeks, survival, and clonal evolution in follow-up.
Interventions
DRUGAvatrombopag
cyclosporine in combination with Avatrombopag to treat
Sponsors
Institute of Hematology & Blood Diseases Hospital, China
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
60 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. elderly patients with V/SAA with a definite diagnosis. 2. age greater than 60 years, male or female. 3. Subjects must complete all screening assessments as outlined in the trial protocol. 4. Able to swallow or administer the drug orally. 5. Cannot tolerate or refuse ATG therapy. 6. No prior treatment with cyclosporine, tacrolimus or hormones or treatment for no more than 2 weeks. 7. No prior application of TPO receptor agonists (including Thrombopoietin, Eltrombopag, Hetrombopag, etc.) or application of TPO receptor agonists for treatment with ≤ 5 total doses and ≤ 7 days of TPO receptor agonist drugs such as Eltrombopag, Hetrombopag, etc. 8. Informed consent must be signed prior to the start of all specific study procedures, in consideration of the patient's condition, or by a member of the patient's immediate family if the patient's signature is not conducive to the treatment of the condition.
Exclusion criteria
No subject shall be enrolled in this study if he/she meets any of the following criteria. 1. known diagnosis of congenital hematopoietic failure disorders (e.g. Fanconi anemia) and other causes of allogeneic cytopenias and bone marrow hypoproliferative disorders (e.g. hemolytic PNH, hypoproliferative MDS/AML, autoantibody-mediated allogeneic cytopenias, etc.); 2. Patients with uncontrolled bleeding and/or infection despite standard treatment. 3. patients with previous history of hematopoietic stem cell transplantation; 4. previous history of thrombosis. 5. Patients with concurrent malignancy or potential cancer on immunosuppressive therapy. 6. Those who are considered unsuitable for enrollment by the investigator.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Percentage of patients with transformation at 24 weeks | 24 weeks of treatment | % of patients with transformation to PNH or MDS,AML, or other disease |
| OR rate at 24 weeks of treatment | 24 weeks of treatment | Percentage of the total number of patients receiving treatment who received a response at 24 weeks of treatment |
| Incidence of Treatment-Emergent Adverse Events as assessed by information on Common Toxicity Criteria (CTC) AE grading at 24 weeks of treatment | 24 weeks of treatment | Incidence of Treatment-Emergent AE by CTCAE |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Percentage of patients with transformation at 12 weeks | 12 weeks of treatment | % of patients with transformation to PNH or MDS,AML, or other disease at 12 weeks |
| Incidence of Treatment-Emergent Adverse Events as assessed by information on Common Toxicity Criteria (CTC) AE grading at 12 weeks | 12 weeks of treatment | Incidence of Treatment-Emergent AE by CTCAE |
| OR rate and CR rate at 12 weeks | 12 weeks of treatment | Percentage of patients who received a response and who receive a complete response at 12 weeks of treatment |
Other
| Measure | Time frame | Description |
|---|---|---|
| OR rate and CR rate at 52 weeks | 52 weeks of treatment | Percentage of patients who received a response and who receive a complete response at 52 weeks of treatment |
| Percentage of patients with transformation at 52 weeks | 52 weeks of treatment | % of patients with transformation to PNH or MDS,AML, or other disease at 52 weeks |
| Incidence of Treatment-Emergent Adverse Events as assessed by information on Common Toxicity Criteria (CTC) AE grading at 52 weeks | 52 weeks of treatment | Incidence of Treatment-Emergent AE by CTCAE |
Countries
China
Contacts
Primary ContactFengkui Zhang, doctor
Backup ContactLi Zhang, doctor
Outcome results
None listed